Skip to main content
SpringerLink
Log in

Calcium channel antagonists: part VI: Clinical pharmacokinetics of first and second-generation agents

  • Calcium Antagonists: Review Series
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Summary

A survey of the pharmacokinetic properties of the three prototypical calcium antagonist agents shows that they have in common a very high rate of hepatic first-pass metabolism with, in the case of verapamil and diltiazem, the formation of an active metabolite that affects the dose during chronic therapy. Therefore, the major factor altering the pharmacokinetic properties and the dose of the drug required is the capacity of the liver to metabolize the drug, which in turn depends on the hepatic blood flow and the activity of the hepatic metabolizing systems. Hence liver disease, a low cardiac output, and coadministration of certain drugs inducing or inhibiting the hepatic enzymes, all indirectly affect the pharmacokinetic properties of the calcium antagonists. There are also other potential drug interactions of a kinetic or dynamic nature that may arise. In general, renal disease has little effect on the pharmacokinetics of calcium antagonists.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Eichelbaum M, Somogyi A. Inter- and intra-subject variations in the first-pass elimination of highly cleared drugs during chronic dosing. Studies with deuterated verapamil.Eur J Clin Pharmacol 1984;26:47–53.

    PubMed  Google Scholar 

  2. Echizen H, Eichelbaum M. Clinical pharmacokinetics of verapamil, nifedipine and diltiazem.Clin Pharmacokinetics 1986;11:425–449.

    Google Scholar 

  3. Freedman SB, Richmond DR, Ashley JJ, et al. Verapamil kinetics in normal subjects and patients with coronary artery spasm.Clin Pharmacol Ther 1981;30:644–652.

    PubMed  Google Scholar 

  4. Neugebauer G. Comparative cardiovascular actions of verapamil and its major metabolites in the anesthetised dog.Cardiovasc Res 1978;12:247–254.

    PubMed  Google Scholar 

  5. Frishman W, Kirsten E, Klein M, et al. Clinical relevance of verapamil plasma levels in stable angina pectoris.Am J Cardiol 1982;50:1180–1184.

    PubMed  Google Scholar 

  6. Keefe DL, Yee Y-G, Kates RE. Verapamil protein binding in patients and in normal subjects.Clin Pharmacol Ther 1981;29:21–26.

    PubMed  Google Scholar 

  7. Woelfel A, Foster JR, McAllister RG, et al. Efficacy of verapamil in exercise-induced ventricular tachycardia.Am J Cardiol 1985;56:292–297.

    PubMed  Google Scholar 

  8. Talano JV, Tommaso C. Slow channel calcium antagonists in the treatment of supraventricular tachycardia.Prog Cardiovasc Dis 1982;25:141–156.

    PubMed  Google Scholar 

  9. Weiss AT, Lewis BS, Halon DA, et al. The use of calcium with verapamil in the management of supraventricular tachyarrhythmias.Int J Cardiol 1983;4:275–280.

    PubMed  Google Scholar 

  10. Reiter MJ, Shand DG, Aanonsen LM, et al. Pharmacokinetics of verpamil: Experience with a sustained intravenous infusion regimen.Am J Cardiol 1982;50:716–721.

    PubMed  Google Scholar 

  11. Schwartz JB, Keefe DL, Kirsten E, et al. Prolongation of verapamil elimination kinetics during chronic oral administration.Am Heart J 1982;104:198–203.

    PubMed  Google Scholar 

  12. Schwartz JB, Abernethy DR, Taylor AA, et al. An investigation of the cause of accumulation of verapamil during regular dosing in patients.Br J Clin Pharmacol 1985;19:512–516.

    PubMed  Google Scholar 

  13. Shand DG, Hammill SC, Aanonsen L, et al. Reduced verapamil clearance during long-term oral administration.Clin Pharmacol Ther 1981;30:701–703.

    PubMed  Google Scholar 

  14. Hesslein P, Gow R, D'Souza J, et al. Age-dependent verapamil kinetics affect pediatric oral dose requirements (abstract).Cardiovasuclar Pharmacotherapy International Symposium, Geneva April 1985;584.

  15. Storstein L, Larsen A, Midtbo K, et al. Pharmacokinetics of calcium blockers in patients with renal insufficiency and in geriatric patients.Acta Med Scand 1983; (Suppl 681):25–30.

    Google Scholar 

  16. Cox JP, O'Boyle CA, Mee F, et al. The antihypertensive efficacy of verapamil in the elderly evaluated by ambulatory blood pressure measurement.J Human Hypertens 1988;2:41–47.

    Google Scholar 

  17. Orlandi C, Marlettini MG, Cassani A, et al. Treatment of hypertension during pregnancy with the calcium antagonist verapamil.Curr Therap Res 1986;39:884–893.

    Google Scholar 

  18. Maxwell DJ, Crawford DC, Curry PVM, et al. Obstetric importance, diagnosis and management of fetal tachycardias.Br Med J 1988;297:107–110.

    Google Scholar 

  19. Mooy J, Shols M, van Baak M, et al. Pharmacokinetics of verapamil in patients with renal failure.Eur J Clin Pharmacol 1985;28:405–410.

    PubMed  Google Scholar 

  20. Marone C, Luisoli S, Bomio F, et al. Body sodium-blood volume state, aldosterone, and cardiovascular responsiveness after calcium entry blockade with nifedipine.Kidney Int 1985;28:658–665.

    PubMed  Google Scholar 

  21. Piepho RW, Culbertson VL, Rhodes RS. Drug interactions with the calcium-entry blockers.Circulation 1987;75 (SUppl V):V181–V194.

    PubMed  Google Scholar 

  22. Rahn KH, Mooy J, Bohm R, et al. Reduction of bioavailability of verapamil by rifampin.N Engl J Med 1985;312:920–921.

    Google Scholar 

  23. Wing LMH, Miners JO, Lillywhite KJ. Verapamil disposition—effects of sulfinpyrazone and cimetidine.Br J Clin Pharmacol 1985;19:385–391.

    PubMed  Google Scholar 

  24. Barbarash RA, Bauman JL, Fischer JH, et al. Near-total reduction in verapamil biovailability by rifampin.Chest 1988;94:954–959.

    PubMed  Google Scholar 

  25. Taburet AM, Singlas E, Colin J-N, et al. Pharmacokinetic studies of nifedipine tablet. Correlation with antihypertensive effects.Hypertension 1985;5 (Suppl II):II29–II33.

    Google Scholar 

  26. Hongo M, Traube M, McAllister RG, et al. Effects of nifedipine on esophageal motor function in humans: Correlation with plasma nifedipine concentration.Gastroenterology 1984;86:8–12.

    PubMed  Google Scholar 

  27. Kleinbloesem CH, Van Brummelen P, Faber H, et al. Variability in nifedipine pharmacokinetics and dynamics: A new oxidation polymorphism in man.Biochem Pharmacol 1984;33:3721–3724.

    PubMed  Google Scholar 

  28. Betocchi S, Bonow RO, Cannon RO, et al. Relation between serum nifedipine concentration and hemodynamic effects in non-obstructive hypertrophic cardiomyopathy.Am J Cardiol 1988;61:830–835.

    PubMed  Google Scholar 

  29. Kuhlmann J, Graefe K-H, Ramsch K-D, et al. Clinical pharmacology. In: Krebs R, ed.Treatment of Cardiovascular Diseases by Adalat R (Nifedipine): Stuttgart: Schattauer, 1986;93–144.

    Google Scholar 

  30. Scott M, Castledon CM, Adam HK, et al. The effect of ageing on the disposition of nifedipine and atenolol.Br J Clin Pharmacol 1988;25:289–296.

    PubMed  Google Scholar 

  31. Endo M, Kanda I, Hosoda S, et al. Prinzmetal's variant form of angina pectoris. Re-evaluation of mechanisms.Circulation 1975;52:33–37.

    PubMed  Google Scholar 

  32. Van Harten J, Burggraaf K, Danhof M, et al. Negligible sublingual absorption of nifedipine.Lancet 1987;2:1363–1365.

    PubMed  Google Scholar 

  33. McAllister RG. Kinetics and dynamics of nifedipine after oral and sublingual doses.Am J Med 1986;81 (Suppl 6A):2–5.

    Google Scholar 

  34. Kleinbloesem CH, Van Brummelen P, Van de Linde JA, et al. Nifedipine: Kinetics and dynamics in healthy subjects.Clin Pharmacol Ther 1984;35:742–749.

    PubMed  Google Scholar 

  35. Chung M, Reitberg DP, Gaffney M, et al. Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system. A controlled-release formulation of nifedipine.Am J Med 1987;83(Suppl 6B):10–14.

    Google Scholar 

  36. Vetrovec GW, Parker VE, Cole S, et al. Nifedipine gastro-intestinal therapeutic system in stable angina pectoris. Results of a multicenter open-label crossover comparison with standard nifedipine.Am J Med 1987;83(Suppl 6B):24–29.

    Google Scholar 

  37. Walley TJ, Heagerty AM, Woods KL, et al. Nifedipine infusion in acute myocardial infarction: Experience in 12 patients.Clin Cardiol 1987;10:800–803.

    PubMed  Google Scholar 

  38. Dilmen U, Calgar MK, Senses DA, et al. Nifedipine in hypertensive emergencies (letter).Br Med J 1983;286:889.

    Google Scholar 

  39. Dickinson DF, Wilson N, Curry P. Use of nifedipine in hypertrophic cardiomyopathy in infants. A report of two cases.Int J Cardiol 1985;2:159–160.

    Google Scholar 

  40. Robertson DRC, Waller DG, Renwick AG, et al. Agerelated changes in the pharmacokinetics and pharmacodynamics of nifedipine.Br J Clin Pharmacol 1988;25:297–305.

    PubMed  Google Scholar 

  41. Gilchrist NL, Nicholls MG, Ewer TC, et al. A comparison of long acting nifedipine and enalapril in elderly hypertensives: A randomised, single-blind, cross-over study.J Human Hypertens 1988;2:33–39.

    Google Scholar 

  42. Walters BNJ, Redman CWG. Treatment of severe pregnancy associated hypertension with the calcium antagonist, nifedipine.Br J Obstet Gynaecol 1984;91:330–336.

    PubMed  Google Scholar 

  43. Bogaert MG, Rosseel MT, Joos R, et al. Plasma concentrations of nifedipine in patients with renal failure.Arzneimittel-Forschung 1984;34:307–308.

    PubMed  Google Scholar 

  44. Martre HR, Sari AM, Taburet C, et al. Haemodialysis does not affect the pharmacokinetics of nifedipine.Br J Clin Pharmacol 1985;20:155–158.

    PubMed  Google Scholar 

  45. Ravens KG. Effect of nifedipine on glucose tolerance in man. In: Lichtlen PR ed.6th International Adalat Symposium. Amsterdam: Excerpta Medica, 1986;367–371.

    Google Scholar 

  46. Daniels AR, Opie LH. Effect of slow-release nifedipine on glucose tolerance. In: Lichtlen PR, ed.6th International Adalat Symposium. Amsterdam: Excerpta Medica, 1986;495–496.

    Google Scholar 

  47. Kleinbloesem CH, Van Brummelen P, Sandberg THW, et al. Kinetic and haemodynamic interactions between nifedipine and propranolol in healthy subjects utilizing controlled rates of drug input. In: Kleinbloesem CH, ed.Nifedipine: Clinical Pharmacokinetics and Haemodynamic Effects 's-Gravenhage: Drukkerij JH Pasmans BV, 1985;151–165.

    Google Scholar 

  48. Schwartz JB, Raizner A, Akers S. The effect of nifedipine on serum digoxin concentrations in patients.Am Heart J 1984;107:669–673.

    PubMed  Google Scholar 

  49. Smith SR, Kendall MJ, Lobo J, et al. Ranitidine and cimetidine: Drug interactions with single dose and steadystate nifedipine administration.Br J Clin Pharmacol 1987;23:331–315.

    PubMed  Google Scholar 

  50. Toyosaki N, Toyo-Oka T, Natsume T, et al. Combination therapy with diltiazem and nifedipine in patients with effort angina pectoris.Circulation 1988;77:1370–1375.

    PubMed  Google Scholar 

  51. Ahmad S. Nifedipine-phenytoin interaction (letter).J Am Coll Cardiol 1984;3:1581–1582.

    Google Scholar 

  52. Deanfield J, Wright C, Krikler S, et al. Cigarette smoking and the treatment of angina with propranolol, atenolol and nifedipine.N Engl J Med 1984;310:951–954.

    PubMed  Google Scholar 

  53. Piepho RW, Bloedow DC, Lacz JP, et al. Pharmacokinetics of diltiazem in selected animal species and human beingsAm J Cardiol 1982;49:525–528.

    PubMed  Google Scholar 

  54. Rovei V, Gomeni R, Mitchard M, et al. Pharmacokinetics and metabolism of diltiazem in man.Acta Cardiologica 1980;35:35–45.

    PubMed  Google Scholar 

  55. Chaffman M, Brogden RN. Diltiazem. A review of its pharmacological properties and therapeutic efficacy.Drugs 1985;29:387–454.

    PubMed  Google Scholar 

  56. Fifer MA, Colucci WS, Lorell BH, et al. Inotropic, vascular and neuroendocrine effects of nifedipine in heart failure: Comparison with nitroprusside.J Am Col Cardiol 1985;5:731–737.

    Google Scholar 

  57. Rovei V, Mitchard M, Morselli PL. Simple, sensitive, and specific gas chromatographic method for the quantification of diltiazem in human body fluids.J Chromatography 1977;138:391–398.

    Google Scholar 

  58. Pozet N, Brazier JL, Aissa AH, et al. Pharmacokinetics of diltiazem in severe renal failure.Eur J Clin Pharmacol 1983;24:635–638.

    PubMed  Google Scholar 

  59. Burges RA, Gardiner DG, Gwilt M, et al. Calcium channel blocking properties of amlodipine in vascular smooth muscle and cardiac muscle in vitro: Evidence for voltage modulation of vascular dihydropyridine receptors.J Cardiovasc Pharmacol 1987;9:110–119.

    PubMed  Google Scholar 

  60. Faulkner JK, McGibney D, Chasseaud LF, et al. The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily.Br J Clin Pharmacol 1986;22:21–25.

    PubMed  Google Scholar 

  61. Webster J, Robb OJ, Jeffers TA, et al. Once daily amlodipine in the treatment of mild to moderate hypertension.Br J Clin Pharmacol 1987;24:713–719.

    PubMed  Google Scholar 

  62. Elliott HL, Meredith PA, Faulkner JK, et al. A comparative evaluation of the disposition of amlodipine in young and elderly subjects (abstract) In:Calcium Antagonists in Hypertension. 25th Anniversary International Symposium, Basel, Switzerland, February 1988.

  63. Abernethy DR, Lambert MD. Amlodipine dynamics and disposition in young and elderly hypertensive patients (abstract). In:Calcium Antagonists in Hypertension. 25th Anniversary International Symposium, Basel, Switzerland, February 1988.

  64. Edgar B, Hoffmann KJ, Lundborg P, et al. Absorption, distribution and elimination of felodipine in man.Drugs 1985;29(Suppl 2):9–15.

    Google Scholar 

  65. Sluiter HE, Huysmans FTM, Thien TA, et al. Haemodynamic, hormonal, and diuretic effects of felodipine in healthy normotensive volunteers.Drugs 1985;29(Suppl 2):26–35.

    Google Scholar 

  66. Agner E, Rehling M, Trap-Jensen J. Haemodynamic effects of single-dose felodipine in normal man.Drugs 1985; 29(Suppl 2):36–40.

    PubMed  Google Scholar 

  67. Andersson OK, Granerus G, Hedner T.. Felodpine. A calcium-inhibiting vasodilator in refractory hypertension.Drugs 1985;29(Suppl 2):102–108.

    PubMed  Google Scholar 

  68. Elmfeldt D, Hedner T. Antihypertensive effects of felodipine compared with placebo.Drugs 1985;29(Suppl 2):109–116.

    Google Scholar 

  69. Ljung B. Vascular selectivity of felodipine.Drugs 1985; 29(Suppl 2):46–58.

    PubMed  Google Scholar 

  70. Hansson BG, Lyngstam G, Lyngstam L, et al. Antihypertensive effect of felodipine combined with β-blockade.Drugs 1985;29(Suppl 2):131–136.

    PubMed  Google Scholar 

  71. Katzman PL, Hulthen UL, Hokfelt B. Catecholamines, renin-angiotensin-aldosterone, and cardiovascular response during exercise following acute and long-term calcium antagonism with felodipine in essential hypertension.J Cardiovasc Pharmacol 1987;10:439–444.

    PubMed  Google Scholar 

  72. Herlitz H, Aurell M, Bjorck S, et al. Renal effects of felodipine in hypertensive patients with reduced renal function.Drugs 1985;29(Suppl 2):192–197.

    PubMed  Google Scholar 

  73. Stieren B, Buhler V, Hege HG, et al. Pharmacokinetics and metabolism of gallopamil. In: Kaltenbach M, Hopf R, eds.Gallopamil. Pharmacological and Clinical Profile of a Calcium Antagonist. Berlin: Springer-Verlag 1984;88–93.

    Google Scholar 

  74. Schran HF, Jaffe JM, Gonasun LM. Clinical pharmacokinetics of isradipine.Am J Med 1988;84(Suppl 3B):80–89.

    PubMed  Google Scholar 

  75. Schran HF, Jaffe JM, Gonasun LL. The pharmacokinetics and metabolism of isradipine (abstract).Cardiovasc Rev and Rep 1987; Special Supplement 3: 7.

    Google Scholar 

  76. Hof RP, Ruegg UT. Pharmacology of the new calcium antagonist isradipine and its metabolites.Am J Med 1988;84(Suppl 3B):13–17.

    PubMed  Google Scholar 

  77. Parker JO, Enjalbert M, Bernstein V. Efficacy of the calcium antagonist isradipine in angina pectoris.Cardiovasc Drugs Ther 1988;1:657–660.

    PubMed  Google Scholar 

  78. Kirkendall WM. Comparative assessment of first-line agents for treatment of hypertension. In: Expanding Role of Calcium Antagonists in Cardiovascular Therapy.Cardiovasc Rev Rep, Special Supplement October 1987;3:9.

    Google Scholar 

  79. Rowe JW. Approach to the treatment of hypertension in older patients. Preliminary results with isradipine.Am J Med 1988;84(Suppl 3B):46–50.

    Google Scholar 

  80. Van den Toren EW, Van Bruggen A, Ruegg PC, et al. Hemodynamic effects of an intravenous infusion of isradipine in patients with congestive heart failure.Am J Med 1988;84(Suppl 3B):97–101.

    PubMed  Google Scholar 

  81. Chellingsworth MC, Willis JV, Broadfoot D, et al. Pharmacokinetics and pharmacodynamics of isradipine (PN 200-110) in young and elderly patients.Am J Med 1988;84(Suppl 3B):72–79.

    Google Scholar 

  82. Thuillez C, Guerret M, Duhaze P, et al. Nicardipine: Pharmacokinetics and effects on carotid and brachial blood flows in normal volunteers.Br J Clin Pharmacol 1984;18:838–847.

    Google Scholar 

  83. Clair F, Bellet M, Guerret M, et al. Hypotensive effect and pharmacokinetics of nicardipine in patients with severe renal failure.Curr Therap Res 1985;38:74–82.

    Google Scholar 

  84. Graham DJM, Dow RJ, Hall DJ, et al. The metabolism and pharmacokinetics of nicardipine hydrochloride in man.Br J Clin Pharmacol 1985;20(Suppl 1):23S-28S.

    PubMed  Google Scholar 

  85. Sorkin EM, Clissold SP. Nicardipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders.Drugs 1987;33:296–345.

    PubMed  Google Scholar 

  86. Urien S, Albengres E, Comte A, et al. Plasma protein binding and erythrocyte partitioning of nicardipine in vitro.J Cardiovasc Pharmacol 1985;7:891–898.

    PubMed  Google Scholar 

  87. Campbell BC, Kelman AW, Hillis WS. Noninvasive assessment of the haemodynamic effects of nicardipine in normotensive subjects.Br J Clin Pharmacol 1985;20(Suppl 1): 55S-61S.

    PubMed  Google Scholar 

  88. Silke P, Graham DJM, Verma SP, et al. Pharmacokinetic, haemodynamic and radionuclide studies with nicardipine in coronary artery disease.Eur J Clin Pharmacol 1986;29:651–657.

    PubMed  Google Scholar 

  89. Bowles MJ, Khurmi NS, O'Hara MJ, et al. Randomized double-blind placebo-controlled comparison of nicardipine and nifedipine in patients with chronic stable angina pectoris.Chest 1986;89:260–265.

    PubMed  Google Scholar 

  90. Forette F, Bellet M, Henry JF, et al. Effect of nicardipine in elderly hypertensive patients.Br J Clin Pharmacol 1985;20(Suppl 1):125S-129S.

    PubMed  Google Scholar 

  91. Brown ST, Freedman D, DeVault GA, et al. Elderly Multicenter Study Group. Safety, efficacy and pharmacokinetics of nicardipine in elderly hypertensive patients.Br J Clin Pharmacol 1985;22(Suppl):289S-295S.

    Google Scholar 

  92. Gengo FM, Fagan SC, Krol G, et al. Nimodipine disposition and haemodynamic effect in patients with cirrhosis and age-matched controls.Br J Clin Pharmacol 1987;3:47–53.

    Google Scholar 

  93. Kirch W, Raemsch KD, Duehrsen U, et al. Clinical pharmacokinetics of nimodipine in normal and impaired renal function.Int J Clin Pharm Res 1984;4:381–384.

    Google Scholar 

  94. Friedel HA, Sorkin EM. Nisoldipine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders.Drugs 1988;36:682–731.

    PubMed  Google Scholar 

  95. Pasanisi F, Meredith PA, Reid JL. The pharmacodynamics and pharmacokinetics of a new calcium antagonist nisoldipine in normotensive and hypertensive subjects.Eur J Clin Pharmacol 1985;29:21–24.

    PubMed  Google Scholar 

  96. Lasseter KC, Shamblen EC, Lettieri J, et al. Doseproportional pharmacokinetics of nisoldipine in healthy volunteers.Clin Pharmacol Ther 1987;41:234.

    Google Scholar 

  97. Ahr G, Wingender W, Kuhlmann J. Pharmacokinetics of nisoldipine. In: Hugenholtz PG, Meyer J, eds.Nisoldipine. Heidelberg: Springer-Verlag, 1987;59–66.

    Google Scholar 

  98. Van Harten J, Van Brummelen P, Zeegers RRECM, et al. The influence of infusion rate on the pharmacoki etics and haemodynamic effects of nisoldipine in man.Br J Clin Pharmacol 1988;25:709–717.

    PubMed  Google Scholar 

  99. Daniels AR, Opie LH. Monotherapy with the calcium channel antagonist nisoldipine for systemic hypertension and comparison with diuretic drugs.Am J Cardiol 1987;60:703–707.

    PubMed  Google Scholar 

  100. Lam J, Chaitman BR, Crean P, et al. A dose-ranging placebo-controlled, double-blind trial of nisoldipine in effort angina: Duration and extent of antianginal effects.J Am Coll Cardiol 1985;6:447–452.

    PubMed  Google Scholar 

  101. Breimer DD, Lodewijks MTM, Van Brummelen P, et al. Pharmacokinetics and haemodynamic effects of nisoldipine in patients with liver cirrhosis.Br J Pharmacol 1986; 89(Suppl):482.

    Google Scholar 

  102. Van Harten J, van Brummelen P, Wilson JHP, et al. Pharmacokinetics and haemodynamic effects of nisoldipine in patients with liver cirrhosis. In: Hugenholtz PG, Meyer J, eds.Nisoldipine. Heidelberg: Springer-Verlag, 1987;76–79.

    Google Scholar 

  103. Joeres R, Ahr G, Hofsetter G, et al. Steady-state pharmacokinetics of nisoldipine in patients with liver disease. In: Hugenholtz PG, Meyer J eds.Nisoldipine. Heidelberg: Springer-Verlag, 1987;80–84.

    Google Scholar 

  104. Boelaert J, Valcke Y, Dammekens H, et al. Nisoldipine pharmacokinetics in renal dysfunction.Acta Pharmacol Toxicol 1986;59(Suppl 5):175.

    Google Scholar 

  105. Kirch W, Stenzel J, Dylewicz P, et al. Influence of nisoldipine on haemodynamic effects and plasma levels of digoxin.Br J Clin Pharmacol 1986;22:155–159.

    PubMed  Google Scholar 

  106. Levine MAH, Ogilvie RI, Leenen FHH. Pharmacokinetic and pharmacodynamic interactions between nisoldipine and propranolol.Clin Pharmacol Ther 1988;43:39–48.

    PubMed  Google Scholar 

  107. Kann J, Krol GJ, Raemsch KD, et al. Bioequivalence and metabolism of nitrendipine administered orally to healthy volunteers.J Cardiovasc Pharmacol 1984;6:S968–S973.

    PubMed  Google Scholar 

  108. Jain AK, McMahon FG, Ryan JR, et al. Efficacy and safety of nitrendipine in patients with severe hypertension: A multiclinic study.J Cardiovasc Pharmacol 1984;6:S1053–S1059.

    PubMed  Google Scholar 

  109. Lasseter KC, Shamblen EC, Murdoch AA, et al. Steady-state pharmacokinetics of nitrendipine in hepatic insufficiency.J Cardiovasc Pharmacol 1984;6:S977–S981.

    PubMed  Google Scholar 

  110. Dylewicz P, Kirch W, Santos SR, et al. Bioavailability and elimination of nitrendipine in liver disease.Eur J Clin Pharmacol 1987;32:563–568.

    PubMed  Google Scholar 

  111. Aronoff G. Pharmacokinetics of nitrendipine in patients with renal failure: Comparison to normal subjects.J Cardiovasc Pharmacol 1984;6:S974–S976.

    PubMed  Google Scholar 

  112. Pinquier JL, Urien S, Lemaire M, et al. Comparative binding of two closely related dihydropyridines (isradipine and darodipine) to serum proteins and erythrocytes.Pharmacology 1988;36:305–312.

    PubMed  Google Scholar 

  113. Andren L, Hansson L, Oro L, et al. Experience with nitrendipine—a new calcium antagonist—in hypertension.J Cardiovasc Pharmacol 1982;4:S387–S391.

    PubMed  Google Scholar 

  114. Kirch W, Hutt HJ, Heidemann H, et al. Drug interactions with nitrendipine.J Cardiovasc Pharmacol 1984;6:S982–S985.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Heart Research Unit, Department of Medicine, University of Cape Town Medical School Observatory, 7925, Cape Town, South Africa

    Lionel H. Opie

Authors
  1. Lionel H. Opie
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Opie, L.H. Calcium channel antagonists: part VI: Clinical pharmacokinetics of first and second-generation agents. Cardiovasc Drug Ther 3, 482–497 (1989). https://doi.org/10.1007/BF01865507

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01865507

Key Words

Search

Navigation